CSIMarket
 
Liquidia Corporation  (NASDAQ: LQDA)
Other Ticker:  
 
 
Price: $16.2550 $-0.01 -0.031%
Day's High: $16.33 Week Perf: 1.85 %
Day's Low: $ 15.97 30 Day Perf: 38.22 %
Volume (M): 752 52 Wk High: $ 16.99
Volume (M$): $ 12,227 52 Wk Avg: $12.31
Open: $15.97 52 Wk Low: $8.26



 Market Capitalization (Millions $) 1,273
 Shares Outstanding (Millions) 78
 Employees 93
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -119
 Cash Flow (TTM) (Millions $) 128
 Capital Exp. (TTM) (Millions $) 4

Liquidia Corporation
Liquidia Corporation is a pharmaceutical company that specializes in the development of therapeutics using its unique particle engineering technology. The company's proprietary PRINT technology allows for the precise engineering of particles to create drug candidates with improved performance and delivery. Liquidia focuses on developing both in-house and partnered therapeutics for various diseases, including respiratory diseases, cancer, and other conditions with significant unmet medical needs. The company aims to leverage its particle engineering capabilities to improve drug efficacy, safety, and patient outcomes.


   Company Address: 419 Davis Drive, Suite 100 Morrisville 27560 NC
   Company Phone Number: 328-4400   Stock Exchange / Ticker: NASDAQ LQDA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MIRM   -1%    
NBY   -7.14%    
PULM   -3.43%    
SRPT   -2.05%    
TBPH   -1.58%    
XERS   -1.1%    
• View Complete Report
   



Clinical Study

Liquidia and Pharmosa Biopharm Collaborate to Innovate PAH Treatment with Sustained Release Treprostinil,

Published Wed, Oct 2 2024 10:00 AM UTC

Advancements in Inhaled Therapies: Liquidia and Pharmosa Biopharm Strengthen Collaboration on Sustained Release Treprostinil Innovative pharmaceutical solutions continue to evolve as global health challenges demand more effective and sustained treatments. In an effort to address the pressing needs in pulmonary arterial hypertension (PAH) management, Liquidia Corporation and ...

Liquidia Corporation

LQDA Faces Decline in Top-line Performance in Q1 2024

Liquidia Corporation (NASDAQ: LQDA) recently reported its financial results for the first quarter ended March 31, 2024, and the figures highlight both challenges and potential opportunities for the company. Despite facing a deficit per share of $-0.54, compared to $-0.18 a year ago, Liquidia Corporation saw growth in its deficit from $-0.42 per share in the previous reporting season. This indicates that the company needs to address its financial performance and find ways to enhance profitability.
One of the key factors contributing to the company's deficit is the decline in revenue. During the reporting season, the revenue decreased by -33.853% to $2.97 million from $4.49 million in the same period a year ago. Additionally, the revenue tumbled by -34.407% sequentially from $4.53 million. These figures highlight the need for Liquidia Corporation to focus on improving its revenue generation strategies to achieve sustainable growth.

Clinical Study

Clearing the Path: Legal and Regulatory Advances Raise Hopes for YUTREPIA's FDA Approval

Published Mon, Apr 1 2024 10:01 AM UTC

In a recent breakthrough for Liquidia Corporation, the U.S. District Court for the District of Delaware has set aside an injunction that had previously prevented the U.S. Food and Drug Administration (FDA) from issuing final approval of Liquidia s New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. This development signifies significant progress and ope...

Liquidia Corporation

Liquidia Corporation Struggles in Challenging Business Environment with -15.466% Revenue Decrease

Liquidia Corporation (NASDAQ: LQDA) has been experiencing a significant decline in its financial performance, as evident from its recent financial results for the fiscal year ending December 31, 2023. The company reported a loss per share of $-0.42, representing a substantial increase from $-0.08 in the previous year and a rise from $-0.24 in the prior reporting period. This indicates a concerning trend of widening losses for Liquidia Corporation.
Furthermore, the company witnessed a considerable decline in revenue, which dropped by -15.466% to $4.53 million compared to $5.36 million in the same reporting period a year ago. Although there was a sequential improvement of 23.192% from $3.68 million, it does not eradicate the overall negative trend. These declining revenue figures raise concerns about Liquidia Corporation's ability to generate sufficient income and maintain a stable financial position.

Product Service News

Liquidia Corporation Responds to United Therapeutics Lawsuit, Asserts Counterclaims and Highlights Patent Office Oversight Failure

Published Mon, Jan 8 2024 1:23 PM UTC

In a recent development in the pharmaceutical industry, Liquidia Corporation (NASDAQ: LQDA) has filed its response and counterclaims against United Therapeutics Corporation (UTHR). This legal battle revolves around alleged patent infringement regarding Liquidia s New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. The filing also sheds light on several ...







Liquidia's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com